Black Diamond Therapeutics Inc Ordinary Shares BDTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $1.39
- Day Range
- $1.31–1.41
- 52-Week Range
- $1.31–4.06
- Bid/Ask
- $1.30 / $1.54
- Shares Outstanding
- 57.47M
- Market Cap
- $75.28M
- Volume/Avg
- 673,414 / 706,797
Key Statistics
- Price/Earnings (Normalized)
- 2.79
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
Valuation
Metric | BDTX |
|---|---|
Price/Earnings (Normalized) | 2.79 |
Price/Book Value | 0.85 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BDTX
Financial Strength
Metric | BDTX |
|---|---|
Quick Ratio | 6.62 |
Current Ratio | 6.92 |
Interest Coverage | — |
Quick Ratio
BDTX
Profitability
Metric | BDTX |
|---|---|
Return on Assets (Normalized) | −16.99% |
Return on Equity (Normalized) | −21.74% |
Return on Invested Capital (Normalized) | −21.80% |
Return on Assets
BDTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|B&vjm% | LOCK|^PmY@ | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|yfXr>TG | LOCK|Z&?< | $95B | |||
| Moderna Inc MRNA | LOCK|ffn<Wm | LOCK|$M@ | $79B | |||
| argenx SE ADR ARGX | LOCK|Tz#p>@ | LOCK|>F$ | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|W^!B&? | LOCK|VT | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|DkJv&S> | LOCK|@<&<x | $30B | |||
| Incyte Corp INCY | LOCK|B%@<<? | LOCK|TjK | $23B | |||
| BioNTech SE ADR BNTX | LOCK|??Gwhr | LOCK|ZH? | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!GQmpQ | LOCK|^#^nc | $19B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|S?V&<df | LOCK|k? | $15B |